1Petr P, Verner M, Van Wyk CJ,et al. Amiodarone -excellent antiarrhythmic drug? ( Happy end after 40 years of problems) [ J ]. J Appl Biomed,2003; 1:127 - 139.
2Najjar TA. Disposition of amiodarone in rats after single and multiple intraperitoneal doses [ J ]. Eur J Drug Metab Pharmacokinet, 2001 ;26: 65- 69.
3Anastasiou N, Nanas JN, Alexopoulos G, et al. Amiodarone concentration in human myocardium after rapid intravenous administration [ J ].Cardiovas Drug Ther , 1999; 13:265 - 270.
4Candinas R, Frielingsdorf J, Ha HR,et al. Myocardial amiodarone concentrations after short - and long - term treatment in patients with end - stage heart failure [ J]. Eur J Clin Pharmacol, 1998 ;53:331 - 336.
5Ortiz M, Gaete L, Asenjo R, et al. Plasma concentrations and amiodarone/desethylamiodarone relations in patients subjected to chronic treatment [ J ]. Rev Med Chil, 1996; 124:77 - 82.
6Roden DM. Mechanism underlying variability in response to drug therapy: Implications for amiodarone use [ J]. Am J Cardiol, 1999; 84( Suppl. 1 ) :S29 - S36.
7Ohyama K, Nakajima M, Nakamura S, et al. A significant role of human cytochrome P4502C8 in amiodarone N - deethylation: An approach to predict the contribution with relative activity factor [ J ]. Drug Metab Dispos,2000; 28:1303 - 1310.
8Soyama A, Hanioka N, Saito Y,et al. Amiodarone N- deethylation by CYP2C8 and its variants, CYP2C8 * 3 and CYP2C8P404A [J].Pharmacol Toxicol,2002 ;91:174 - 178.
9Nanas JN, Mason JW . Pharmacokinetics and regional electrophysiological effects of intracoronary amiodarone administration [J]. Circulation,1995 ;91:451 -461.
10Ohyama K, Nakajima M, Suzuki M ,et al. Inhibitory effects of amiodarone and its N - deethylated metabalite on human cytochrome P450 activities: prediction of in vivo drug interactions [ J ]. Br J Clin Pharmacol,2000 ;49:244 - 253.
